TABLE 2

Characteristics, treatment regimens, and microbiologic responses of 166 patients with M. avium complex lung diseasea

CharacteristicDaily therapy (n = 77)Intermittent therapy (n = 89)
Favorable microbiological responses (n = 52)Unfavorable microbiological responses (n = 25)P valueFavorable microbiological responses (n = 73)Unfavorable microbiological responses (n = 16)P value
Sex, male21 (40.4)12 (48.0)0.52727 (37.0)8 (50.0)0.334
Age (yr)60 (51–69.5)59 (52–71)0.85361 (53.5–69)59.5 (50–67.5)0.567
Body mass index (kg/m2)19.8 (17.5–20.7)20.2 (16.9–22.0)0.35520.9 (19.1–22.3)19.6 (17.9–22.0)0.283
Nonsmoker76 (98.1)24 (96.0)0.54772 (98.6)16 (100)1.000
Comorbid disease
    Bronchiectasis37 (71.2)15 (60.0)0.32870 (95.9)15 (93.8)0.554
    Previous tuberculosis33 (63.5)16 (64.0)0.96324 (32.9)7 (43.8)0.408
    Previous NTM lung disease10 (19.2)3 (12.0)0.52910 (13.7)2 (12.5)1.000
    Cancer12 (23.1)4 (16.0)0.47413 (17.8)4 (25.0)0.497
    Chronic lung disease5 (9.6)4 (16.0)0.4612 (2.7)01.000
    Diabetes mellitus3 (5.8)1 (4.0)1.0006 (8.2)00.586
    Chronic liver disease2 (3.8)3 (12.0)0.3223 (4.1)01.000
    Chronic heart disease1 (1.9)1 (4.0)0.5472 (2.7)1 (6.3)0.452
    Chronic kidney disease1 (1.9)01.0001 (1.4)01.000
Etiology0.1900.226
    M. avium27 (51.9)9 (36.0)44 (60.3)7 (43.8)
    M. intracellulare25 (48.1)16 (64.0)29 (39.7)9 (56.3)
Fibrocavitary form15 (28.8)11 (44.0)0.18800
Positive sputum smearb34 (65.4)21 (84.0)0.06515 (20.5)8 (50.0)0.025
Additional treatmentc
    Injectable drugs11 (21.2)10 (40.0)0.08200
    Surgical resection3 (5.8)3 (12.0)0.38300
  • a Data are presented as median (interquartile range) or number (%).

  • b At the initiation of antibiotic treatment.

  • c Within 12 months of the start of antibiotic treatment.